To assess the in vivo impact of CNPY3 knockdown on tumor progression and 5-FU sensitivity, mice were divided into four groups: KD-Con + PBS, KD + PBS, KD-Con + 5-FU, and KD + 5-FU. The gene discussed is CNPY3; the disease is neoplasm.